The efficacy, safety, and adverse events of azapirones in anxiety disorders: A systematic review and meta-analysis of randomized controlled trials

被引：4

作者：

Rossano, Flavia ^{[1
]}

Caiazza, Claudio ^{[1
]}

Zotti, Nicolas ^{[1
]}

Viacava, Luca ^{[1
]}

Irano, Antonella ^{[1
]}

Solini, Niccolo ^{[1
]}

Pistone, Luca ^{[1
]}

Pezone, Rosanna ^{[1
]}

Cilmi, Flavia ^{[1
]}

Ricci, Claudio ^{[1
]}

De Prisco, Michele ^{[2
,3
,4
]}

Iasevoli, Felice ^{[5
,6
]}

Kishi, Taro ^{[7
]}

Solmi, Marco ^{[8
,9
,10
]}

de Bartolomeis, Andrea ^{[5
,6
]}

Fornaro, Michele ^{[1
,11
]}

机构：

[1] Univ Sch Med Feder II, Dept Neurosci Reprod Sci & Odontostomatol, Clin Sect Psychiat & Psychol, Reprod Sci, Naples, Italy

[2] Hosp Clin Barcelona, Bipolar & Depress Disorders Unit, C Villarroel 170, Barcelona 08036, Spain

[3] Inst Invest Biomed August Pi & Sunyer IDIBAPS, C Villarroel 170, Barcelona 08036, Spain

[4] Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid, Spain

[5] Univ Sch Med Naples Feder II, Dept Neurosci Reprod Sci & Odontostomatol, Unit Treatment Resistant Psychosis, Sect Psychiat, Naples, Italy

[6] Univ Sch Med Naples Federico II, Lab Mol Translat & Psychiat, Naples, Italy

[7] Fujita Hlth Univ, Sch Med, Dept Psychiat, Toyoake, Aichi 4701192, Japan

[8] Univ Ottawa, Dept Psychiat, Ottawa, ON, Canada

[9] Ottawa Hosp, Dept Mental Hlth, On Track Champlain Episode Psychosis Program 1, Ottawa, ON, Canada

[10] Charite, Dept Child & Adolescent Psychiat, Berlin, Germany

[11] Univ Napoli Federico II, Psichiatria, Via Sergio Pansini n5,Edificio 18, I-80131 Naples, Italy

来源：

EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2023年 / 76卷

关键词：

Azapirones; Anxiety; Systematic review; Meta-analysis; GENERALIZED ANXIETY; DOUBLE-BLIND; PANIC DISORDER; CLINICAL-EVALUATION; BENZODIAZEPINE USE; LOCUS-COERULEUS; BUSPIRONE; DIAZEPAM; PLACEBO; MULTICENTER;

D O I：

10.1016/j.euroneuro.2023.07.008

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Azapirones have been proposed as anxiety and mood modulators. We assessed azapirones' vi-ability in anxiety disorders via systematic review and random-effects meta-analysis, inquiring PubMed/MEDLINE/CENTRAL/WHO-ICTRP/WebOfScience/VIP up-to 05/01/2023. We conducted sensitivity, and subgroup analyses assessing heterogeneity, publication bias, risk of bias, and confidence in the evidence within the GRADE framework. Symptom reduction (mean differ-ence/MD), study-defined response (risk ratios/RRs), and acceptability were co-primary out-comes. Adverse events and withdrawal were secondary. Seventy studies were included. In gen-eralized anxiety disorder (GAD), azapirones largely outperformed placebo (MD =-4.91, 95%C.I.[-5.91,-3.90], Hedges'g-1.37 [-1.02,-0.73]), k = 22, n = 2,567; RR = 1.64, 95%C.I.[1.45, 1.86], k = 9, n = 1,346). While azapirones overlapped benzodiazepines in symptom reduction (MD = -0.12, 95%C.I.[-0.70, 0.45], k = 34, n = 3,160), they were slightly outperformed in response rate (RR = 0.94, 95%C.I.[0.90, 0.99], k = 18, n = 2,423). Azapirones overlapped SRIs (MD = 0.09, 95%C.I.[-0.49, 0.67], k = 8, n = 747; RR = 0.97, 95%C.I.[0.89, 1.07], k = 7, n = 737). Confidence in estimates was high/moderate vs. placebo, moderate/low vs. benzodiazepine, very-low vs. SRIs. Azapirones failed to outperform the placebo in panic and social anxiety disorders. Aza-pirones overlapped placebo and SRIs in drop-out rates, while they showed higher treatment discontinuation rates than benzodiazepines (RR = 1.33, 95%C.I.[1.16, 1.53], k = 23, n = 2,768). Azapirones caused less sedation/fatigue/drowsiness/weakness/cognitive issues than benzodi-azepines, resembling placebo. They caused more nausea and dizziness than placebo, more headache and nausea than benzodiazepines, and less nausea and xerostomia than SRIs. Aza-pirones proved effective and relatively well-tolerated for GAD. They should be preferred over benzodiazepines, especially in the long-term, considering their lower sedation and addiction potential, representing a potential SRI alternative. Further research is warranted to prove ef-ficacy in panic and social anxiety.& COPY; 2023 Elsevier B.V. and ECNP. All rights reserved.

引用

页码：23 / 51

页数：29

共 120 条

[1]

Administration U.F.a.D. Release F.N., 2016, FDA REQ STRONG WARN

[2] Benzodiazepine Misuse in the Elderly: Risk Factors, Consequences, and Management [J].